Cytek Q2 revenue up 24% to $49.7M; net loss widens to $4.4M

Cytek Biosciences, Inc.

Revenue $49.7M (+24% YoY); organic revenue $41.5M (+3%) excl. $8.2M from Luminex acquisition.
Gross margin 57% vs 61% YoY; adjusted gross margin 60% vs 64%.
Operating loss $9.1M (vs $0.9M loss Q2 2022); net loss $4.4M (vs $0.7M).
Adjusted EBITDA $1.5M vs $4.8M prior year; cash $298.8M.
Shipped 100th Cytek Aurora Cell Sorter; FY2023 revenue guidance reaffirmed at $205M-$220M.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Cytek Biosciences, Inc. reported the second quarter ended June 30, 2023 results: revenue $49.7 million, net income $4.4 million. Guidance reaffirmed.

Period: the second quarter ended June 30, 2023
Revenue: $49.7 million
Net income: $4.4 million
Guidance: reaffirmed
Result: reported results

Exact text from the filing

(“Cytek Biosciences” or “Cytek”) (Nasdaq: CTKB) today reported financial results for the second quarter ended June 30, 2023. Recent Highlights • Total revenue was $49.7 million, representing 24% growth over the second quarter of 2022 • Total revenue on a non-GAAP constant currency basis was $50.0 million • Organic revenue for Cytek’s existing product

View on SEC.gov

Browse all earnings releases →

Cytek Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-23-206235

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.